Results 51 to 60 of about 6,071 (199)

Healthcare Utilization in Children Following Hospitalization for RSV‐ Versus Non‐RSV Related Lower Respiratory Tract Infections: A Nationwide Retrospective Study

Pediatric Pulmonology, Volume 61, Issue 1, January 2026.
ABSTRACT Introduction Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections (LRTIs) in young children. Additionally, RSV is associated with long‐term respiratory morbidities. This study evaluates acute and long‐term healthcare utilization (HCU) in infants hospitalized with RSV‐associated LRTI (RSV‐LRTI) compared to ...
Guy Hazan, Mai Ofri, Lital Hertz, Oliver Martyn, David Greenberg   +4 more
wiley   +1 more source

Risk of RSV-related hospitalization is associated with gestational age in preterm (born at 29–34 wGA) infants without outpatient palivizumab administration

Human Vaccines & Immunotherapeutics, 2023
Palivizumab has been shown to decrease RSV-related hospitalization (RSVH) risk and reduce RSVH severity. American Academy of Pediatrics (AAP) guidance on administration of palivizumab has changed over time; in 2014, palivizumab was no longer recommended ...
Elizabeth R. Packnett, Isabelle H. Winer, Abiola Oladapo, Matthew Wojdyla   +3 more
doaj   +1 more source

Access to palivizumab among children at high risk of respiratory syncytial virus complications in English hospitals [PDF]

, 2022
Objectives: Palivizumab is a monoclonal antibody which can prevent infection with respiratory syncytial virus (RSV). Due to its high cost, it is recommended for high-risk infants only.
Standing, JF, Hardelid, P, Tompsett, D, De Stavola, B, Almossawi, O, Smyth, R, Zylbersztejn, A, Gudka, N   +7 more
core  

Bridging Genomics and Clinical Medicine: RSVrecon Enhances RSV Surveillance With Automated Genotyping and Clinically Important Mutation Reporting

Influenza and Other Respiratory Viruses, Volume 20, Issue 1, January 2026.
ABSTRACT Background Respiratory Syncytial Virus (RSV) causes significant respiratory infections, particularly in young children and elderly adults. Genetic variations in the fusion (F) protein can reduce the efficacy of vaccination and monoclonal antibody treatments, emphasizing the need for genomic surveillance of this virus.
Lei Li, Haidong Yi, Jessica N. Brazelton, Richard J. Webby, Randall T. Hayden, Gang Wu, Diego R. Hijano   +6 more
wiley   +1 more source

The Medicaid Cost of Palivizumab [PDF]

Journal of the Pediatric Infectious Diseases Society, 2014
To the editor—Borse et al. [1] describe an economic analysis of respiratory syncytial virus (RSV) prophylaxis for infants in Alaska's Yukon-Kuskokwim Delta. The authors should be congratulated for evaluating this important question with a robust analysis. As these infants are almost entirely insured by Medicaid, we wish to clarify the net Medicaid cost
Ambrose, Christopher S., McLaurin, Kimmie K.   +1 more
openaire   +1 more source

Spatial and temporal variability of respiratory syncytial virus disease seasonality in Japan, 2012–2024

Pediatrics International, Volume 68, Issue 1, January/December 2026.
Abstract Background Understanding infectious disease seasonality is crucial to inform immunization timing and risk communications. This study aimed to describe trends in respiratory syncytial virus (RSV) seasonality in Japan by determining thresholds across 47 prefectures using public health surveillance data. Methods Weekly RSV cases per sentinel (CPS)
Takeshi Arashiro, Ichiro Morioka, Naruhiko Ishiwada, Oliver Martyn, Rolf Kramer, Jing Jin, Amanda Pinho, Ewen Corbelon, Satoshi Kusuda   +8 more
wiley   +1 more source

Appropriate prophylaxis with restrictive palivizumab regimen in preterm children in Sweden

, 2004
AIM: Palivizumab (Synagis) was registered in Sweden in 1999 for prophylaxis against respiratory syncytial virus (RSV) in premature infants. The high costs and the limited knowledge of the efficacy of this substance have led to debate about how and when ...
Eriksson, M., Ewald, Uwe,, Linde, A., Lindroth, M., Naver, Lars, Schollin, J.   +5 more
core   +2 more sources

Effects of palivizumab prophylaxis on respiratory syncytial virus (RSV) infections in Montenegro

The Turkish Journal of Pediatrics
Background. Respiratory syncytial virus (RSV) is one of the most common pathogens causing severe lower respiratory tract disease in infancy and childhood.
Envera Lekic, Ljubinka Dragas, Drasko Nikcevic, Jasmina Lekic, Ana Dedic, Ljiljana Sulovic   +5 more
doaj   +1 more source

Therapeutic Antibodies for Mosquito‐Borne Orthoflavivirus Infections: Discovery, Engineering Approaches, and Advances in mRNA‐Based Delivery Systems

Advanced Therapeutics, Volume 8, Issue 12, December 2025.
This review explores how antibody engineering and display technologies are driving therapeutic advances against mosquito‐borne orthoflaviviruses such as Zika, dengue, and yellow fever viruses. It highlights diverse neutralizing targets on the envelope protein, including the conserved fusion loop, and discusses how Fc engineering, rational antigen ...
Ana Clara Barbosa Antonelli, Lucas Silva Rodrigues, Maria Clara Moura Pinheiro, Sylvia Barbosa Pinhate, Marcelo de Macedo Brígido, Andréa Queiroz Maranhão   +5 more
wiley   +1 more source

Respiratory Syncytial Virus Epidemiology During and After Covid‐19 Pandemic in Africa: Systematic Review and Meta‐Analysis

Health Science Reports, Volume 8, Issue 12, December 2025.
ABSTRACT Background and Aims Respiratory syncytial virus (RSV) is a major agent of acute respiratory infections in children and the elderly. RSV epidemiology has been changed by the since Covid‐19 pandemic and this review aimed to assess the extent of this change in Africa.
Moussa Issa, Adamou Lagare, Goni A. M. Bachir, Arnol Bowo ‐Ngandji, Fatimata Hassane, Larwanou Harouna Magagi, Doutchi Mahamadou, Haoua Seini, Eric Adehossi, Alzouma Mayaki Zoubeirou   +9 more
wiley   +1 more source